Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 22;21(22):8829.
doi: 10.3390/ijms21228829.

Clinical Perspectives of ERCC1 in Bladder Cancer

Konstantinos Koutsoukos  1 , Angeliki Andrikopoulou  1 , Nikos Dedes  1 , Flora Zagouri  1 , Aristotelis Bamias  2 , Meletios-Athanasios Dimopoulos  1
Affiliations
Review

Clinical Perspectives of ERCC1 in Bladder Cancer

Konstantinos Koutsoukos et al. Int J Mol Sci. .

Abstract

ERCC1 is a key regulator of nucleotide excision repair (NER) pathway that repairs bulky DNA adducts, including intrastrand DNA adducts and interstrand crosslinks (ICLs). Overexpression of ERCC1 has been linked to increased DNA repair capacity and platinum resistance in solid tumors. Multiple single nucleotide polymorphisms (SNPs) have been detected in ERCC1 gene that may affect ERCC1 protein expression. Platinum-based treatment remains the cornerstone of urothelial cancer treatment. Given the expanding application of neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer, there is an emerging need for biomarkers that could distinguish potential responders to cisplatin treatment. Extensive research has been done regarding the prognostic and predictive role of ERCC1 gene expression and polymorphisms in bladder cancer. Moreover, novel compounds have been recently developed to target ERCC1 protein function in order to maximize sensitivity to cisplatin. We aim to review all the existing literature regarding the role of the ERCC1 gene in bladder cancer and address future perspectives for its clinical application.

Keywords: ERCC1; biomarker; bladder cancer; excision repair cross-complementation group 1; urothelial.

PubMed Disclaimer

Conflict of interest statement

K.K. has received honoraria by Roche, BMS, MSD and IPSEN. A.B. has received honoraria by Roche, BMS, Astra Zeneca, MSD. M.-A.D. has received honoraria from participation in advisory boards from Amgen, Bristol-Myers-Squibb, Celgene, Janssen, Takeda. F.Z. has received honoraria for lectures and has served in an advisory role for Astra-Zeneca, Daiichi, Eli-Lilly, Merck, Novartis, Pfizer, and Roche. The remaining authors declare no conflict of interest.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Saginala K., Barsouk A., Aluru J.S., Rawla P., Padala S.A. Alexander Barsouk Epidemiology of Bladder Cancer. [(accessed on 12 September 2020)]; Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151633/ - PMC - PubMed
    1. Patel V.G., Oh W.K., Galsky M.D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 2020:caac.21631. doi: 10.3322/caac.21631. - DOI - PubMed
    1. Bellmunt J., Orsola A., Leow J.J., Wiegel T., De Santis M., Horwich A. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014;25:iii40–iii48. doi: 10.1093/annonc/mdu223. - DOI - PubMed
    1. Flaig T.W., Spiess P.E., Chair V., Agarwal N., Bangs R., Patient Advocate M., Boorjian S.A., Buyyounouski M.K., Chang S., Downs T.M., et al. NCCN Clinical Practice Guidelines in Oncology Version 3.2020 Bladder Cancer. J. Natl. Compr. Cancer Netw. 2020;18:329–354. doi: 10.6004/jnccn.2020.0011. - DOI - PubMed

MeSH terms